References

Global burden of hepatitis B virus: current status, missed opportunities and a call for action

10.1038/s41575-023-00760-9 · 2023 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

2024 latest report on hepatitis B virus epidemiology in China: current status, changing trajectory, and challenges

10.21037/hbsn-2024-754 · 2025 · External reference

Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection

10.1111/j.1365-2567.2007.02691.x · 2008 · External reference

Changes of Treg and Th17 cells balance in the development of acute and chronic hepatitis B virus infection

10.1186/1471-230x-12-43 · 2012 · External reference

Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B

10.4049/jimmunol.177.1.739 · 2006 · External reference

Dynamic change in Th17/regulatory T cell ratio in peripheral blood of patients with acute hepatitis B and its significance

10.3760/cma.j.issn.1007-3418.2016.08.002 · 2016 · External reference

Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice

10.1002/hep.25765 · 2012 · External reference

Temporal analysis of early immune responses in patients with acute hepatitis B virus infection

10.1053/j.gastro.2009.06.054 · 2009 · External reference

HBcAg-specific CD4+CD25+ regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection

10.1007/s11373-006-9129-z · 2007 · External reference

Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection

10.1002/hep.20649 · 2005 · External reference

Memory regulatory T cells increase only in inflammatory phase of chronic hepatitis B infection and related to Galectin-9/Tim-3 interaction

10.1038/s41598-017-15527-x · 2017 · External reference

Significance of the balance between regulatory T (Treg) and T helper 17 (Th17) cells during hepatitis B virus related liver fibrosis

10.1371/journal.pone.0039307 · 2012 · External reference

Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B

10.1002/hep.23273 · 2010 · External reference

Enhanced high-mobility group box 1 (HMGB1) modulates regulatory T cells (Treg)/T helper 17 (Th17) balance via toll-like receptor (TLR)-4-interleukin (IL)-6 pathway in patients with chronic hepatitis B

10.1111/jvh.12152 · 2014 · External reference

Regulatory T cells (Tregs) in liver fibrosis

10.1038/s41420-023-01347-8 · 2023 · External reference

Levels of hepatic Th17 cells and regulatory T cells upregulated by hepatic stellate cells in advanced HBV-related liver fibrosis

10.1186/s12967-017-1167-y · 2017 · External reference

Treg/Th17 imbalance and its clinical significance in patients with hepatitis B-associated liver cirrhosis

10.1186/s13000-019-0891-4 · 2019 · External reference

The dual role of regulatory T cells in hepatitis B virus infection and related hepatocellular carcinoma

10.1111/imm.13738 · 2024 · External reference

Unresolved reference

External reference

Single-cell landscape of immune cells in human livers affected by HBV-related cirrhosis

10.1016/j.jhepr.2023.100883 · 2023 · External reference

Single-cell landscape of immune cells during the progression from HBV infection to HBV cirrhosis and HBV-associated hepatocellular carcinoma

10.3389/fimmu.2023.1320414 · 2023 · External reference

CTLA4(+)CD4(+)CXCR5(-)FOXP3(+) T cells associate with unfavorable outcome in patients with chronic HBV infection

10.1186/s12865-022-00537-w · 2023 · External reference

Inhibition of SATB1 expression in regulatory T cells contributes to hepatitis B virus-related chronic liver inflammation

10.3892/mmr.2014.2752 · 2015 · External reference

Changes of Th17/Treg ratio in the transition of chronic hepatitis B to liver cirrhosis and correlations with liver function and inflammation

10.3892/etm.2019.7299 · 2019 · External reference

Correlation between Th17 and nTreg cell frequencies and the stages of progression in chronic hepatitis B

10.3892/mmr.2015.4618 · 2016 · External reference

Dynamic changes of Treg and Th17 cells and related cytokines closely correlate with the virological and biochemical response in chronic hepatitis B patients undergoing nucleos(t)ide analogues treatment

10.5812/hepatmon.15332 · 2013 · External reference

Effects of the Treg/Th17 cell balance and their associated cytokines in patients with hepatitis B infection

10.3892/etm.2014.2104 · 2015 · External reference

Treg/Th17 cell balance in patients with hepatitis B virus-related acute-on-chronic liver failure at different disease stages

10.1155/2021/9140602 · 2021 · External reference

Dysregulated anti-oxidant signalling and compromised mitochondrial integrity negatively influence regulatory T cell function and viability in liver disease

10.1016/j.ebiom.2023.104778 · 2023 · External reference

Intrahepatic T helper 17 cells recruited by hepatitis B virus X antigen-activated hepatic stellate cells exacerbate the progression of chronic hepatitis B virus infection

10.1111/jvh.13352 · 2020 · External reference

Increased Th17 cells contribute to disease progression in patients with HBV-associated liver cirrhosis

10.1111/j.1365-2893.2011.01561.x · 2012 · External reference

Daclizumab: mechanisms of action, therapeutic efficacy, adverse events and its uncovering the potential role of innate immune system recruitment as a treatment strategy for relapsing multiple sclerosis

10.3390/biomedicines7010018 · 2019 · External reference

Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis

10.1001/archneurol.2009.16 · 2009 · External reference

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

10.1126/science.1202947 · 2011 · External reference

Role of PD-1 in regulating T-cell immunity

10.1007/82_2010_116 · 2011 · External reference

FDA approval summary: tremelimumab in combination with durvalumab for the treatment of patients with unresectable hepatocellular carcinoma

10.1158/1078-0432.ccr-23-2124 · 2024 · External reference

Unresolved reference

External reference

Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis

10.1186/s40249-023-01128-6 · 2023 · External reference

Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update

10.1200/jco.20.01757 · 2020 · External reference

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

10.1007/s00262-006-0225-8 · 2007 · External reference

Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans

10.1073/pnas.1316796110 · 2013 · External reference

Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome

10.1158/1078-0432.ccr-14-0830 · 2015 · External reference

Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease

10.1126/scitranslmed.3005265 · 2013 · External reference

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial

10.1136/annrheumdis-2018-214229 · 2019 · External reference

Exploring the pathogenic role and therapeutic implications of interleukin 2 in autoimmune hepatitis

10.1007/s10620-020-06562-2 · 2021 · External reference

mTOR signaling, Tregs and immune modulation

10.2217/imt.14.84 · 2014 · External reference

Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells

10.1182/blood-2007-06-094482 · 2008 · External reference

Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid

10.1126/science.1145697 · 2007 · External reference

Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression

10.4049/jimmunol.181.4.2277 · 2008 · External reference

Hepatic vitamin D receptor expression is negatively associated with liver inflammation and fibrosis in patients with chronic HBV infection

10.1007/s10238-022-00919-9 · 2023 · External reference

IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation

10.4049/jimmunol.1203013 · 2013 · External reference

Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice

10.1053/j.gastro.2012.05.049 · 2012 · External reference

Neutralization of interleukin-17 attenuates cholestatic liver fibrosis in mice

10.1111/sji.12395 · 2016 · External reference

A review of the safety of interleukin-17A inhibitor secukinumab

10.3390/ph15111365 · 2022 · External reference

Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials

10.1186/s13075-023-03257-7 · 2024 · External reference

Cirrhosis-associated immune dysfunction

10.1038/s41575-021-00520-7 · 2022 · External reference

Hepatitis virus reactivation in patients with psoriasis treated with secukinumab in a real-world setting of hepatitis B or hepatitis C infection

10.1007/s40261-022-01163-5 · 2022 · External reference

Bimekizumab versus secukinumab in plaque psoriasis

10.1056/nejmoa2102383 · 2021 · External reference

Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis

10.2147/ce.s33940 · 2014 · External reference

The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells

10.1016/j.cell.2006.07.035 · 2006 · External reference

Novel RORγt inverse agonists limit IL-17-mediated liver inflammation and fibrosis

10.1093/jimmun/vkaf014 · 2025 · External reference

Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment

10.1371/journal.pone.0013869 · 2010 · External reference

Effect of entecavir on CD4+ T-cell subpopulations in patients with chronic hepatitis B

10.5604/16652681.1193705 · 2016 · External reference

The effect of entecavir therapy on immune status in chronic hepatitis B patients

10.22034/iji.2019.39409 · 2019 · External reference

Predictive value of Th17 and Treg cells at baseline for HBsAg loss in chronic hepatitis B patients with low HBsAg quantification treated with pegylated interferon and nucleos(t)ide analogue

10.1016/j.livres.2023.04.002 · 2023 · External reference

Pegylated interferon α-2b up-regulates specific CD8+ T cells in patients with chronic hepatitis B

10.3748/wjg.v16.i48.6145 · 2010 · External reference

Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans

10.1016/j.jhep.2022.08.035 · 2023 · External reference

Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus

10.1016/j.jtauto.2022.100152 · 2022 · External reference

Chimeric antigen receptor (CAR) T-cell therapy: engineering immune cells to treat liver diseases

10.1016/j.jhep.2025.06.007 · 2025 · External reference

Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease

10.1007/s00281-022-00940-w · 2022 · External reference

Regulatory T cell therapy in autoimmune liver disease and transplantation

10.1016/j.jhepr.2025.101394 · 2025 · External reference

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

10.1016/s2468-1253(23)00148-6 · 2023 · External reference

Hepatitis B virus (HBV) core antigen-specific regulatory T cells confer sustained remission to anti-HBV therapy in chronic hepatitis B with acute exacerbation

10.1016/j.humimm.2010.11.001 · 2011 · External reference

Therapeutic targeting of liver inflammation and fibrosis by nanomedicine

10.3978/j.issn.2304-3881.2014.11.02 · 2014 · External reference

Histone/protein deacetylase inhibitor therapy for enhancement of Foxp3+ T-regulatory cell function posttransplantation

10.1111/ajt.14749 · 2018 · External reference

Low hepatitis B virus-specific T-cell response in males correlates with high regulatory T-cell numbers in murine models

10.1002/hep.29155 · 2017 · External reference

Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient

10.1016/j.jhep.2014.10.001 · 2015 · External reference

Spatial transcriptomics of healthy and fibrotic human liver at single-cell resolution

10.1038/s41467-024-55325-4 · 2025 · External reference

MIBI-TOF: a multiplexed imaging platform relates cellular phenotypes and tissue structure

10.1126/sciadv.aax5851 · 2019 · External reference

Association of increased programmed death ligand 1 expression and regulatory T cells infiltration with higher hepatocellular carcinoma recurrence in patients with hepatitis B virus pre-S2 mutant after curative surgical resection

10.3390/v14061346 · 2022 · External reference

Immune regulation and therapeutic application of T regulatory cells in liver diseases

10.3389/fimmu.2024.1371089 · 2024 · External reference